Revive Therapeutics Ltd
OTC:RVVTF
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
R
|
Revive Therapeutics Ltd
CNSX:RVV
|
4.4m CAD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
965.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
594B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
292.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD |
Loading...
|
|
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
91B GBP |
Loading...
|
Market Distribution
Other Profitability Ratios
Revive Therapeutics Ltd
Glance View
Revive Therapeutics Ltd. engages in the research, development, and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid pharmaceuticals markets. The company is headquartered in Toronto, Ontario. The company went IPO on 2013-07-12. The firm is focused on the research and development of therapeutics for infectious diseases and rare disorders. The firm is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
